Research Library

TriStar Technology Group LLC has had the privilege of working with innovative organizations around the world to support their research and intellectual property development over the past decade. Part of our core strategy is to also collaborate with leading platform manufacturers to generate innovative research publications.

TriStar Original and Collaborative Research

As of 2019 TriStar Technology Group has begun to actively develop our own research by collaborating with promising technology, biotechnology, and research organizations. We will continue to update this table with our new research. To view a publication simply click the "view" button on the correlated row.
1Multidimensional Gene Expression Models for Characterizing Response and Metastasis in Solid Tumor Samples04/01/2019Cofactor GenomicsPoster
2Tumor Heterogeneity and Primary Versus Metastatic Evaluation of PD-L104/01/2019Istituto Oncologico del MediterraneoPoster
3Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second line immunotherapy12/12/2019Nanostring TechnologiesPoster
4Comparative analysis of the immune microenvironment in histological subtypes of lung and breast cancer using a tissue microarray (TMA) comprising invasive margin (IM) and tumor center (TC)12/12/2019Seoul National University Medical College, Seoul, South KoreaPoster

Papers, Patents, and Reports That Cite TriStar

Since TriStar Technology Group's inception, we have continued to take steps to ensure that our service and product offerings come from a scientific and not a commodity point of view. We have been able to support the biomarker research efforts of many teams across the globe by continuing to provide product and service offerings that are in line with the latest trends in oncology research. In the table below you will find papers, reports, and patent applications that cite TriStar Technology Group LLC as a vendor.
1Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor‐DSep-12Chugai Pharmaceutical Co. Ltd.Paper
2Targeting Nuclear EGFR: Strategies for Improving Cetuximab Therapy in Lung CancerSep-14University of Wisconsin, U.S. Army Medical Research and Materiel CommandReport
3Anti-EpCAM antibody and uses thereof4/4/2007 - 04/02/2028Alfasigma SpAPatent Application
4Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK InhibitorsMar-17AstraZenecaPaper
5Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast CancerMay-14University of Wisconsin, U.S. Army Medical Research and Materiel CommandPaper
6CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancersJul-08Seattle Genetics, CeleraPaper
7The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate CancerNov-16Agensys, Seattle Genetics Inc.Paper
8Identification of Genes Required for the Survival of Prostate Cancer CellsJun-11University of Rochester U.S. Army Medical Research and Materiel CommandReport
9Immunohistochemical Detection of BRCA-1 and BRCA-2 Expression in Human Breast and Ovarian TumorsJul-13MerckPaper
10pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistryNov-18AstraZeneca, Fred Hutchinson Cancer Research CentrePaper
Inquiry Item Removed. Undo
  • No products in the cart.